Learn more about how TANOVEA-CA1 benefits veterinarians and pet owners.

TANOVEA-CA1 – the first FDA conditionally approved drug for the treatment of lymphoma in dogs – has demonstrated a 77 percent overall response and a 45 percent complete response rate, supporting a reasonable expectation of efficacy in both naïve and relapsed/refractory lymphoma.

Available in all 50 states, TANOVEA-CA1 is an exciting new cancer treatment for dogs that is specifically designed to target and kill canine lymphoma cells. TANOVEA-CA1 is easy to administer, with only five doses for a full treatment, and is generally well-tolerated in clinical studies.

This canine lymphoma treatment is a convenient option for pet owners and clinics. Veterinarians administer TANOVEA-CA1 every three weeks with a simple, 30-minute intravenous infusion.

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-475.

 

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.

 

Important Safety Information: TANOVEA®-CA1 is indicated for the treatment of lymphoma in dogs. In clinical trials, the most frequently reported adverse reactions included decreased white blood cell count, diarrhea, vomiting, decreased or loss of appetite, weight loss, decreased activity level, and skin problems. Serious and sometimes fatal respiratory complications, including pulmonary fibrosis have occurred in dogs treated with TANOVEA-CA1. Do not use in West Highland White Terriers and use with caution in other terrier breeds. Owners should take extra care when handling and cleaning up after their dog for five days after treatment. Please see the package insert for full prescribing information, warnings and precautions.